Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Semler Scientific, Inc. (Nasdaq: SMLR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents cover both its healthcare operations and its Bitcoin treasury activities, offering investors insight into how the company reports revenues and expenses from its medical device and software business alongside unrealized gains and losses from changes in the fair value of its Bitcoin holdings.
In its periodic reports, Semler Scientific presents financial statements that reflect income from operations in its healthcare segment, operating expenses such as engineering and product development, sales and marketing, and general and administrative costs, as well as line items related to digital assets. The filings detail the fair value of Bitcoin classified as intangible digital assets, changes in that fair value, and the impact on pre-tax income. They also describe capital-raising transactions, including at-the-market equity offering programs and 4.25% convertible senior notes due 2030, and provide information on stockholders’ equity.
Current reports on Form 8-K document material events such as the adoption and evolution of Semler Scientific’s Bitcoin treasury strategy, the master loan agreement with Coinbase Credit Inc. secured by Bitcoin collateral, and the agreement in principle to settle a civil investigative demand from the U.S. Department of Justice. Other 8-K filings describe a strategic plan to realign operations through headcount reductions and expense curtailment, a non-executive retention program, executive officer changes and the Agreement and Plan of Merger providing for the acquisition of Semler Scientific by Strive, Inc. in an all-stock transaction.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as segment performance, digital asset disclosures, capital structure changes and merger-related information. Investors can also use the filings to monitor topics like BTC Yield as a disclosed key performance indicator, the structure of Bitcoin-related financing arrangements and other regulatory disclosures relevant to SMLR.
Semler Scientific, Inc. reported the results of its 2025 annual stockholder meeting held on September 5, 2025. Stockholders elected William H.C. Chang as a Class I director to serve until the 2028 annual meeting and approved, on an advisory basis, the compensation of the company’s named executive officers.
Stockholders approved an amendment to the restated certificate of incorporation to increase authorized common stock from 50,000,000 shares to 210,000,000 shares, giving the company significantly more capacity to issue stock in the future. They did not approve a separate amendment that would have authorized 42,000,000 shares of blank-check preferred stock. Stockholders also ratified the selection of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025.
Semler Scientific insider activity: Dr. Douglas Murphy-Chutorian, Semler Scientific (SMLR) CEO and director, exercised options and completed related sales on 08/25/2025. He exercised a stock option with a $2.56 exercise price to acquire 60,000 shares; those underlying options were fully vested and immediately exercisable. To cover the exercise cost and withholding taxes he sold 28,604 shares at a weighted average price of $30.54 per share (sales executed between $30.33 and $30.92). He transferred beneficial ownership of 31,396 shares into a family trust (co-trustee with spouse) and reports indirect beneficial ownership of 186,709 shares following the transactions.
Semler Scientific (SMLR) reported a Form 144 notice showing a proposed sale of 60,000 common shares through APEX CLEARING on the NASDAQ with an aggregate market value of $1,847,400.00. The filing states the shares were acquired and are being sold on 08/25/2025 via exercise of stock options from Semler Scientific, Inc., and lists 14,804,693 shares outstanding for the company. The filer certifies they are not aware of undisclosed material adverse information about the issuer. No other sales in the past three months were reported.
Citadel-related entities and Kenneth Griffin report beneficial ownership of Semler Scientific (SMLR) common stock totaling approximately 697,427 shares, representing 5.1% of the class. The filing is a joint Schedule 13G covering Citadel Securities GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin. Ownership totals per entity range from 570 shares to 697,997 shares for Mr. Griffin. The groups report no sole voting or dispositive power; all reported voting and dispositive power is shared. The percentages are calculated on 13,688,405 shares outstanding as of June 30, 2025.
Semler Scientific (Common Stock, CUSIP 81684M104) is reported as beneficially owned in aggregate by a group of affiliated Susquehanna entities and Capital Ventures International totaling 597,196 shares, equal to 4.4% of the 13,688,405 shares outstanding as of June 30, 2025. The filing states that Susquehanna Securities, LLC includes 202,600 options to acquire shares. Individual reporting persons disclose allocated voting and dispositive powers, with Susquehanna Securities reporting 398,215 sole voting/dispositive shares and Capital Ventures International reporting 181,494 sole voting/dispositive shares; smaller sole holdings are reported for G1 Execution Services and SIG Brokerage.
This Schedule 13G/A (Amendment No. 2) presents a passive-group disclosure: the reporting persons state the holdings were not acquired to influence control. The filing includes issuer and reporting persons' addresses and is signed by Brian Sopinsky on 08/13/2025.
Morgan Stanley and its subsidiary Morgan Stanley Investment Management Inc. have filed a Schedule 13G reporting a new passive position in Semler Scientific, Inc. (SMLR).
As of 30 Jun 2025 the firms collectively own 790,603 common shares, equal to 5.8 % of the outstanding equity. Morgan Stanley discloses 790,437 shares with shared voting power and 789,925 shares with shared dispositive power, while MSIM lists 788,492 shares under both shared voting and dispositive authority. Neither entity holds sole voting or dispositive rights.
The Schedule 13G is filed under Rule 13d-1(b), indicating the stake is held in the ordinary course of business and is not intended to influence control. A joint filing agreement (Exhibit 99.1) and subsidiary identification (Exhibit 99.2) are included. Signatures were provided on 07 Aug 2025.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
